In rats, six cytochrome P450 (P450) 2D isoforms have been genetically identified. Nonetheless, there is little evidence of catalytic properties of each CYP2D isoform. In this study, using recombinant CYP2D isoforms (rat CYP2D1, CYP2D2, CYP2D3, and CYP2D4 and human CYP2D6) or hepatic microsomes, we investigated the catalytic specificity toward bufuralol, debrisoquine, and propranolol, which are frequently used as CYP2D substrates. Bufuralol was oxidized to three metabolites by rat and human hepatic microsomes. 1-Hydroxybufuralol was the major metabolite. 12-Ethenylbufuralol, one of the others, was identified as a novel metabolite. The formation of 1-hydroxybufuralol and 12-ethenylbufuralol in hepatic microsomes was inhibited by anti-CYP2D antibody, suggesting that these metabolites were formed by CYP2D isoforms. All rat and human recombinant CYP2D isoforms possessed activity for the 1-hydroxylation of bufuralol, indicating that this catalytic property was common to all CYP2D isoforms. However, the 12-ethenylation of bufuralol was catalyzed only by rat CYP2D4 and human CYP2D6. Debrisoquine was oxidized to two metabolites, 3-hydroxydebrisoquine, and 4-hydroxydebrisoquine, by hepatic microsomes. Recombinant CYP2D2 and CYP2D6 had very high levels of activity for the 4-hydroxylation of debrisoquine with low K m values. Only CYP2D1 had a higher level of 3-hydroxylation than 4-hydroxylation activity. Propranolol 4-hydroxylation was catalyzed by CYP2D2, CYP2D4, and CYP2D6. The 7-hydroxylation of propranolol was catalyzed only by CYP2D2. In conclusion, in rats, bufuralol 12-ethenylation activity was specific to CYP2D4 and debrisoquine 4-hydroxylation and propranolol 7-hydroxylation activities were specific to CYP2D2. These catalytic activities are useful as a probe for rat CYP2D isoforms.
Cytochrome P450 (P450 1 ) 2D isoforms have been identified in several mammalian species and are involved in the monooxygenation of various chemicals including antidepressants (e.g. desipramine), ␤-blockers (e.g. propranolol), antiarrhythmics (e.g. sparteine), and others (e.g. dextromethorphan and methadone) in the liver (Eichelbaum and Gross, 1990; Gonzalez, 1996) . In humans, only one isoform, CYP2D6, is expressed in various tissues including the liver, kidney, brain, placenta, breast, and lung (Niznik et al., 1990; RomkesSparks et al., 1994; Carcillo et al., 1996; Hakkola et al., 1996; Guidice et al., 1997; Huang et al., 1997) . On the other hand, in rats, six isoforms (CYP2D1, CYP2D2, CYP2D3, CYP2D4, CYP2D5, and CYP2D18) have been identified by genomic analysis (Kawashima and Strobel, 1995; Gonzalez, 1996; Nelson et al., 1996) . Among these six, CYP2D5 and CYP2D18 have over 95% similarity in amino acid sequence to CYP2D1 and CYP2D4, respectively (Gonzalez et al., 1987; Matsunaga et al., 1989; Kawashima and Strobel, 1995) . Similar to human CYP2D6, the six rat CYP2D isoforms are expressed in various tissues such as liver, kidney, and brain (Komori, 1993; Hellmold et al., 1995; Kawashima and Strobel, 1995; Masubuchi et al., 1996; Zhang et al., 1996; Hiroi et al., 1998) . Interestingly, the mRNA of each isoform showed a specific tissue distribution in our previous study (Hiroi et al., 1998) . CYP2D2 and CYP2D3 mRNAs are mainly expressed in the liver, kidney, and small intestinal mucosa, which are constantly exposed to xenobiotics such as drugs, food components, and environmental contamination. In contrast, CYP2D1/5 mRNA is expressed systemically in various tissues. CYP2D4/18 mRNA is expressed in brain, adrenal gland, ovary, testis, and gonecystis, in addition to liver, kidney, and small intestinal mucosa. CYP2D4 has also been identified in rat breast (Hellmold et al., 1995) . The specific tissue distributions of the rat CYP2D isoforms suggest that each isoform has specific catalytic properties and plays specific roles in various tissues. However, very little information on the similarities and/or differences in catalytic properties among these six isoforms is available at present. It is difficult to purify each CYP2D isoform from rat tissues, because of their highly homologous amino acid sequences (Gonzalez et al., 1987; Matsunaga et al., 1989; Matsunaga et al., 1990; Kawashima and Strobel, 1995) . To solve this problem, we isolated full-length cDNAs of rat CYP2D1, CYP2D2, CYP2D3, and CYP2D4 and human CYP2D6. Each enzymatic protein was expressed in yeast cells, and each recombinant enzyme was used as an isolated enzyme (Imaoka et al., 1996; Wan et al., 1997) .
In the present study, we focused our effort on the catalytic similarities and differences between rat CYP2D isoforms and investigated the catalytic activities of five recombinant isoforms (human CYP2D6 and rat CYP2D1, CYP2D2, CYP2D3, and CYP2D4) toward bufuralol, debrisoquine, and propranolol, typical substrates for CYP2D. We found specific activity for rat CYP2D2 and CYP2D4 and the activities to be useful as a probe for these isoforms.
CA) operating in the positive ion spray mode, set with a spray needle voltage of 4.5 kV, capillary temperature of 225°C, sheath gas flow of 80 U, and auxiliary gas flow of 10 U. A TSKgel ODS-80Ts column (4.6 ϫ 250 mm; TOSOH Corp.) was used for separation. The column temperature was maintained at 40°C. The mobile phase consisting of 0.1% trifluoroacetic acid and acetonitrile (90:10, v/v) was delivered at a flow rate of 1 ml/min. Mass spectral data for 3-hydroxydebrisoquine were obtained with the same mass spectrometer also operating in the positive ion spray mode, set with a spray needle voltage of 4.5 kV, capillary temperature of 275°C, sheath gas flow of 85 U, and auxiliary gas flow of 15 U.
NMR Analysis of 3-Hydroxydebrisoquine. Debrisoquine (20 mol) was incubated with recombinant CYP2D1 (5 nmol) and NADPH (13 mol) in a final volume of 10 ml of 0.1 M potassium phosphate buffer, pH 7.4, at 37°C for 20 min. The reaction was started by adding NADPH and stopped with 200 l of 60% perchloric acid. After centrifugation, the supernatant was evaporated to dryness and dissolved in 0.5 ml of water. The solution was applied to a preparative HPLC column (21.5 ϫ 300 mm, TOSOH Corp.), and the column temperature was maintained at 40°C. The mobile phase containing 0.1% trifluoroacetic acid and acetonitrile (90:10, v/v) was delivered at a flow rate of 6 ml/min. The eluate containing 3-hydroxydebrisoquine was collected by monitoring at 215 nm and evaporated to dryness. The residue was dissolved in [ 2 H]acetonitrile (CH 3 CN) and subjected to 1 H-NMR measurements with a NMR spectrometer (UNITY INOVA 500; Varian Inc., Palo Alto, CA).
Others. Enzyme kinetic parameters (K m and V max ) were analyzed according to a nonlinear least-square regression based on the Michaelis-Menten equation using the computer software Microcal Origin (version 5.0J, Origin LabCorp, Northampton, MA).
Results and Discussion
Bufuralol Metabolism. Bufuralol is a typical substrate for CYP2D isoforms. The level of 1Ј-hydroxybufuralol, a major metabolite of bufuralol, is often measured as an index of CYP2D activity and/or levels, and the amount of 1Ј-hydroxybufuralol formed from bufuralol is known to be small in CYP2D6-deficient metabolizers (Gonzalez, 1996) . The HPLC profile of bufuralol metabolism by rat hepatic microsomes is shown in Fig. 1a . Bufuralol was metabolized to three metabolites, namely 1Ј-hydroxybufuralol, M1-bufuralol, and M2-bufuralol. The structures of M1-bufuralol and M2-bufuralol were deduced by LC/MS/MS/MS (Fig. 2) . In the case of M1-bufuralol, the LC/MS analysis indicated an apparent [M ϩ H ϩ ] at m/z 276. The LC/MS/MS analysis indicated fragments at m/z 220 and at m/z 202. The LC/MS/MS/MS analysis indicated a fragment at m/z 160. Judging from these results and the spectra of bufuralol (data not shown), M1-bufuralol was identified as 1Ј-oxobufuralol. 1Ј-Oxobufuralol has been reported as a bufuralol metabolite in humans, eluted just after 1Ј-hydroxybufuralol on HPLC . In the case of Recently 1Ј2Ј-ethenylbufuralol has been demonstrated to be a metabolite formed by CYP2D6 (Hanna et al., 2001) . However, this is the first report that 1Ј2Ј-ethenylbufuralol was formed from bufuralol by rat CYP2D isoforms.
To reveal the contribution of the CYP2D isoforms to the formation of the three bufuralol metabolites, inhibition experiments using anti-CYP2D antibodies were performed (Fig. 3) . Anti-CYP2D antibodies inhibited both 1Ј-hydroxylation (1Ј-hydroxylbufuralol formation) and 1Ј2Ј-ethenylation (1Ј2Ј-ethenybufuralol formation) activities in rat and human hepatic microsomes, to less than 10% of the control activity, which was measured without any antibodies. 1Ј-Carboxylation (1Ј-oxobufuralol formation) activity was also partly inhibited by anti-CYP2D antibodies. These results suggested that the 1Ј2Ј-ethenylation and 1Ј-hydroxylation of bufuralol were catalyzed by CYP2D isoforms and that the 1Ј-carboxylation was catalyzed by several isoforms including CYP2D. Next, we measured the bufuralol oxidation activity of each P450 isoform (Fig. 4, Table 1 ). All CYP2D isoforms tested in this study possessed activity for the 1Ј-hydroxylation of bufuralol. Human CYP2D6 had the highest 1Ј-hydroxylation activity of all isoforms tested, followed by CYP2D2 and CYP2D4. Among the purified rat P450 isoforms, CYP1A and CYP2C11 have this activity but at low levels. In the case of 1Ј-carboxylation, human CYP2D6 had very high activity. In rats, CYP2D2, CYP2D3, and CYP2D4 had this activity. CYP1A1 had a much higher level of 1Ј-carboxylation activity than the rat CYP2D isoforms. These results supported the findings that anti-CYP2D antibodies did not inhibit completely the 1Ј-carboxylation of bufuralol (Fig. 3) . Both CYP2D and CYP1A isoforms were considered to contribute to the formation of 1Ј-carboxybufuralol from bufuralol in rats. Mimura et al. (1994) has demonstrated that M-1, a metabolite that was eluted just after 1Ј-hydroxybufuralol on HPLC, was formed
FIG. 3. Inhibition of bufuralol metabolism by anti-CYP2D antibodies in rat and
human hepatic microsomes.
Rat (F, E) and human (OE, ‚) hepatic microsomes were preincubated with various amounts of anti-CYP2D antibodies (F, OE) or control antibodies (E, ‚) at room temperature for 15 min. After preincubation, bufuralol and 0.1 M potassium phosphate buffer, pH 7.4 were added to the mixture on ice. The reaction was initiated by adding NADPH (0.2 mol). Control activity was measured without any antibodies and is shown as 100% on the y-axis. by CYP1A1 and CYP1A2 in rats, though it was not documented as 1Ј-carboxybufuralol. Also in humans, the 1Ј-carboxylation of bufuralol has been demonstrated to be mediated by CYP1A2 . CYP2D4 and CYP2D6 had high bufuralol 1Ј2Ј-ethenylation activity. CYP2D1 did not have this activity. CYP2D2 and CYP2D3 showed this activity but at low levels: less than 15% of the CYP2D4 activity. Other purified rat P450 isoforms were much less active than CYP2D4 or did not have any activity. Taken together with the data shown in Fig. 3 demonstrating that anti-CYP2D antibody almost completely inhibited the 1Ј2Ј-ethenylation of bufuralol by rat and human hepatic microsomes, these results indicated that the 1Ј2Ј-ethenylation activity was specific to rat CYP2D4 and human CYP2D6.
1Ј2Ј-Ethenylbufuralol is considered to be formed both from bufuralol by ethenylation and from 1Ј-hydroxybufuralol by dehydration. To clarify whether 1Ј2Ј-ethenylbufuralol was formed from bufuralol via 1Ј-hydroxybufuralol, we assayed the 1Ј2Ј-ethenylation activity using 1Ј-hydroxybufuralol as a substrate (Table 1) . We could not detect 1Ј2Ј-ethenylbufuralol when 1Ј-hydroxybufuralol was used as a substrate at a final concentration of 30 M. In contrast, we could detect 1Ј2Ј-ethenylbufuralol using bufuralol as a substrate, even though the final concentration of bufuralol was 20 M. The results suggested that 1Ј2Ј-ethenylbufuralol was formed directly from bufuralol, not via 1Ј-hydroxybufuralol.
We summarized the metabolism of bufuralol by CYP2D in Fig. 5 . Three metabolites were produced by rat and human hepatic microsomes. All human and rat CYP2D isoforms tested in this study had 1Ј-hydroxylation activity, a potential probe of CYP2D activity (Gonzalez, 1996) . The 1Ј-hydroxylation activity is considered to be common to all CYP2D isoforms. We have already demonstrated that CYP2D2 had an extremely low K m value for bufuralol 1Ј-hydroxylation activity compared with other CYP2D isoforms (Chow et al., 1999) . Therefore in rats, CYP2D2 is likely to predominantly catalyze the 1Ј-hydroxylation of bufuralol, though all CYP2D isoforms have this activity. 1Ј-Oxobufuralol, which was eluted just after 1Ј-hydroxybufuralol on HPLC, was catalyzed by both CYP1A and the CYP2D isoforms. The 1Ј2Ј-ethenylation of bufuralol was catalyzed by only rat CYP2D4 and human CYP2D6. A specific activity for CYP2D4 had not been reported until now. This is the first report that in rats, CYP2D4 has specific activity for the 1Ј2Ј-ethenylation of bufuralol.
Debrisoquine Metabolism. Debrisoquine is a classical substrate for CYP2D isoforms and a probe for CYP2D activity as well as bufuralol. The level of 4-hydroxydebrisoquine formed from debrisoquine is used in the judgment of CYP2D6 polymorphism in vivo (Woolhouse et al., 1979) . The HPLC profile of debrisoquine metabolism by rat hepatic microsomes is shown in Fig. 1b . Human hepatic microsomes also showed the same profile (data not shown). Debrisoquine was metabolized to 4-hydroxydebrisoquine and M1-debrisoquine. 4-Hydroxydebrisoquine was eluted at a retention time of about 8.5 min and was a major metabolite. M1-Debrisoquine eluted at a retention time of 11 min. The structure of M1-debrisoquine was identified by LC/MS and NMR analysis. The MS spectrum of M1-debrisoquine gave a protonated molecular ion at m/z 192, and collision-induced decomposition led to a fragment at 174 (Fig. 6) . The ion at m/z 174, a loss of 18 Da, suggested cleavage of a hydroxy group from the protonated molecular ion [M ϩ H ϩ ]. Because the mass number of debrisoquine was 175, the ion at m/z 192 was suggested to be a protonated ion of hydroxylated debrisoquine at the 1-, 3-, or
FIG. 4. Catalytic activities of rat and human P450 isoforms.
Bufuralol was incubated with recombinant CYP2D isoforms (10 pmol) and NADPH (0.2 mol) in a final volume of 0.5 ml of 0.1 M potassium phosphate buffer, pH 7.4, at 37°C for 10 min. In reconstitution systems using purified P450 isoforms, bufuralol was incubated with purified P450 isoforms (10 pmol), NADPH-P450 reductase (0.4 units), dilauroylphosphatidylcholine (5 g), sodium cholate (0.1 mg), and NADPH (0.2 mol) in a final volume of 0.5 ml of 0.1 M potassium phosphate buffer, pH 7.4, at 37°C for 10 min. Isoforms 1 to 5 are recombinant CYP2D isoforms. Isoforms 6 to 13 are P450 isoforms purified from rat tissues. 1, recombinant CYP2D1; 2, recombinant CYP2D2; 3, recombinant CYP2D3; 4, recombinant CYP2D4; 5, recombinant CYP2D6; 6, purified CYP1A1; 7, purified CYP1A2; 8, purified CYP2A2; 9, purified CYP2B1; 10, purified CYP2C11; 11, purified CYP2D1; 12, purified CYP2E1; 13, purified CYP3A2 To identify the hydroxylated position on debrisoquine, a 1 H-NMR spectrum of M1-debrisoquine was measured. The peaks of 1-CH2 (sharp AB quartet), 3-CH-OH (broad singlet) and 4-CH2 (broad AB quartet) were observed at 4.4, 5.6, and 3.1 ppm, respectively (data not shown). Based on these data, M1-debrisoquine was assigned as 3-hydroxydebrisoquine. 3-Hydroxydebrisoquine has been reported to be one of the debrisoquine metabolites produced by CYP2D6 (Eiermann et al., 1998) .
To clarify that the CYP2D isoforms are responsible for the formation of 4-hydroxy and 3-hydroxydebrisoquines, inhibition experiments were performed using anti-CYP2D antibodies and a chemical inhibitor (Fig. 7) . Anti-CYP2D antibodies inhibited both 4-hydroxylation and 3-hydroxylation by rat hepatic microsomes, to less than 5% of the control activity. Quinine, which is a typical chemical inhibitor for CYP2D isoforms (Otton et al., 1984) , also inhibited the 4-hydroxylation and 3-hydroxylation activities of rat hepatic microsomes, though some 3-hydroxylation activity remained. These results indicated that both 4-hydroxylation and 3-hydroxylation were catalyzed by CYP2D isoforms in rats.
We investigated the catalytic properties of CYP2D isoforms toward debrisoquine using recombinant enzymes. Human CYP2D6 and rat CYP2D2 had high levels of 4-hydroxylation activity (Fig. 8) . The K m values of CYP2D2 and CYP2D6 for the 4-hydroxylation of debrisoquine were low, 6.87 Ϯ 0.62 and 13.0 Ϯ 1.1 M, respectively (Table  2) . CYP2D1 also had 4-hydroxylation activity; however, its activity a, rat hepatic microsomes were preincubated with various amounts of anti-CYP2D antibodies (F, OE) or control antibodies (E, ‚) at room temperature for 15 min. After preincubation, debrisoquine and 0.1 M potassium phosphate buffer, pH 7.4, were added to the mixture on ice. The reaction was initiated by adding NADPH (0.2 mol). (F, E) and (OE, ‚) indicate 4-hydroxylation activity and 3-hydroxylation activity, respectively. Control activity was measured without any antibodies and is shown as 100% on the y-axis. b, debrisoquine was incubated with rat hepatic microsomes (0.2 mg) and NADPH (0.2 mol) in a final volume of 0.5 ml of 0.1 M potassium phosphate buffer, pH 7.4, at 37°C for 10 min in the presence of quinine. (F) and (OE) indicate 4-hydroxylation activity and 3-hydroxylation activity, respectively.
FIG. 8. Metabolism of debrisoquine by CYP2D isoforms.
Debrisoquine was incubated with recombinant CYP2D isoforms and NADPH (0.2 mol) in a final volume of 0.5 ml of 0.1 M potassium phosphate buffer, pH 7.4, at 37°C for 15 min. Debrisoquine and its metabolites were detected using HPLCfluorometry.
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at ASPET Journals on April 13, 2017 dmd.aspetjournals.org was quite weak, and the K m value of CYP2D1 for 3-hydroxylation was 152 Ϯ 7 M, much higher than 13.1 Ϯ 1.0 M, that of CYP2D2. These results suggested that in rats, the 4-hydroxylation of debrisoquine was almost a specific function of CYP2D2. CYP2D6 and CYP2D2 also had 3-hydroxylation activity, but it was weaker than their 4-hydroxylation activity; therefore, the relative ratio of 3-hydroxylation to 4-hydroxylation activity for CYP2D2 and CYP2D6 was low, 0.18 and 0.65, respectively (Fig. 8) . Only CYP2D1 had higher 3-hydroxylation than 4-hydroxylation activity; therefore, the relative activity ratio of CYP2D1 was 7.46, very high.
We summarized the pathways of debrisoquine metabolism by CYP2D in Fig. 9 . In the present study, debrisoquine was metabolized to 4-hydroxydebrisoquine and 3-hydroxydebrisoquine by rat and human hepatic microsomes. Debrisoquine has been demonstrated to be metabolized to three metabolites, 4-hydroxydebrisoquine, 3-hydroxydebrisoquine, and 1-hydroxydebrisoquine by CYP2D6 (Eiermann et al., 1998) . In this study, 1-hydroxydebrisoquine was not detected. Human CYP2D6 had high debrisoquine 4-hydroxylation activity. In rats, only CYP2D2 had a very high level of 4-hydroxylation activity, indicating that this activity was specific for CYP2D2 in rats (AlDabbagh et al., 1981; Gonzalez et al., 1987) . Dark Agouti rats have very low levels of debrisoquine 4-hydroxylation activity. Not enough CYP2D2 protein is expressed in these rats (Yamamoto et al., 1998) . These findings support that CYP2D2 catalyzes predominantly the 4-hydroxylation of debrisoquine in rats. 3-Hydroxydebrisoquine was formed by rat CYP2D1, rat CYP2D2, and human CYP2D6. Only CYP2D1 had higher 3-hydroxylation than 4-hydroxylation activity. This was a specific property of CYP2D1. Since the K m value of CYP2D1 for the 3-hydroxylation of debrisoquine was high, CYP2D1 may contribute to this activity when the concentration of substrate is high enough.
Propranolol Metabolism by Rat Hepatic Microsomes. We further investigated the metabolic properties of CYP2D using propranolol (Table 3) . Propranolol is used clinically as a ␤-blocker and is one of the substrates of CYP2D (Masubuchi et al., 1993; Masubuchi et al., 1994) . Propranolol is known to be metabolized to four main metabolites (4-, 5-, 7-hydroxylpropranolol and N-desisopropylpropranolol) by rat hepatic microsomes (Masubuchi et al., 1993) . In humans, propranolol was metabolized to three main metabolites (4-, 5-hydroxylproranolol and N-desisopropylpropranolol) (Masubuchi et al., 1994) . In humans and rats, the N-desisopropylation has been reported to be catalyzed by CYP1A and/or CYP2C isoforms, not CYP2D isoforms Yoshimoto et al., 1995) . CYP2D6 had high 4-and 5-hydroxylation activities but very low 7-hydroxylation activity. In rats, CYP2D2 and CYP2D4 had higher levels of 4-hydroxylation activity than CYP2D1 and CYP2D3. The 5-hydroxylation of propranolol was catalyzed by several CYP2D isoforms, but the levels of activity catalyzed by rat CYP2D isoforms were very low. The 7-hydroxylation was catalyzed only by CYP2D2 in rats. The 7-hydroxylation activity of rat hepatic microsomes was inhibited by anti-CYP2D antibodies to less than 10% of the control (data not shown). This suggests that the 7-hydroxylation activity was specific to CYP2D2.
In conclusion, we demonstrated the catalytic properties of the rat and human CYP2D isoforms. Each CYP2D isoform had specific properties in terms of catalytic activity. CYP2D4 selectively metabolized bufuralol through 1Ј2Ј-ethenylation whereas CYP2D2 selectively metabolized debrisoquine through 4-hydroxylation and propranolol via 7-hydroxylation. These activities are useful as a probe for rat CYP2D isoforms. 
